• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Nanoparticle Drug Delivery Market Report Product Image

Nanoparticle Drug Delivery Market Report

  • Published: September 2007
  • Region: Global
  • 301 Pages
  • Cientifica Ltd

This report will give Pharma investors a comprehensive understanding on the impact of nanotechnologies on the pharmaceutical market and companies, which include companies that are producing nanomaterials/technologies to enable better drug delivery compounds (drug delivery company) and companies that are using nano-enabled formulations to enhance drug delivery (drug formulation company).

This report will provide an in-depth discussion on recent developments of nanoparticleenabled drug delivery systems (DDS) and future opportunities. It is tailored for investors who plan to invest in the pharmaceutical industry with an eye towards how nanoparticle drug delivery technology will impact the economics of the pharmaceutical market.

The information includes business summaries, technology core competencies, how nanoparticle adds value for investors in drug delivery companies, comercialization strategies, intellectual property and available markets.

There are 58 case studies on nanoparticle DDS listed according to 3 categories:

-Delivery Method/Routes of administration

Oral administration
Transdermal delivery
Injectable delivery
Topical delivery
Inhaled/nasal/pulmonary READ MORE >

TABLE OF EXHIBITS

EXECUTIVE SUMMARY

AIM, SCOPE AND ORGANIZATION OF REPORT
CIENTIFICA NANOTECHNOLOGY MODEL
Definitions of Nanotechnologies
Major Assumptions
BACKGROUND

MARKET FORECAST & OVERVIEW

INTRODUCTION TO THE MARKETS

NANOPHARMACEUTICALS
NANOTECHNOLOGY IN DRUG DELIVERY
NANOBIOTECHNOLOGY IN DRUG DELIVERY
OTHER APPLICATIONS FOR NANOMATERIALS IN THE MEDICAL AND PHARMACEUTICAL SECTOR
TRENDS AND NEEDS
ROADMAP
NANOTECHNOLOGY INFLUENCE IN PHARMACEUTICAL VALUE CHAIN
ANALYTICAL TECHNIQUES FOR NANOPARTILE DRUG DELIVERY
Properties
Production Of Nanoparticles
Measuring Dispersion Of Nanoparticles
Analysis Of Carrier Systems
NANOPARTICLES AS DRUG CARRIERS
What Can Nanoparticles Do In Drug Delivery
Overview On The Types Of Nanoparticles In Drug Delivery
The First Nanoparticle Drug Delivery System Reaches The Market
Present And Future Applications
PROJECTED PRODUCT PIPELINE FOR NANOPARTICLE IN DRUG DELIVERY MARKET
Overview Of Nanoparticle Drug Delivery System (DDS) In Various Applications
Available Applications Of Nanopartcile In Drug Delivery

DRUG DELIVERY CHALLENGES -- WHY DRUG DELIVERY & WHY NANOPARTICLES

THE NEED FOR BETTER DRUG THERAPY
THE NEED FOR DRUG SOLUBILITY
THE NEED FOR SITE-SPECIFIC AND ORGAN-SPECIFIC IN FUNCTION

DRIVERS AND OPPORTUNITIES FOR NANOPARTICLE DRUG DELIVERY

THE AIM OF DRUG TARGETING
REASONS WHY THE DRUG DELIVERY MARKET IS RAPIDLY EXPANDING
MARKET DRIVERS FOR ENHANCED DRUG DELIVERY
THE ADVANTAGES OF USING POLYMERIC NANOPARTICLES (PNPS) IN DRUG DELIVERY
EXPANDING GOVERNMENTAL FUNDING DRIVES THE NANOBIOTECHNOLOGY MARKET
HOW DRUG COMPANIES ARE REACTING TO THIS EXPANSION

FUTURE BARRIERS AND CHALLENGES

BIG PHARMACEUTICAL COMPANIES RELUCTANT TO INVEST IN UNTRIED TECHNOLOGIES
LACK OF REGULATORY CASE LAW
LONG ADMISSION PROCEDURES INCLUDING FOR EXAMPLE SEVERAL CLINICAL TRIALS
A NEED FOR RAPID SCREENING METHODS
SCALABILITY OF NANOPARTICLE PRODUCTION
AN URGENT NEED FOR ANALYTICAL METHODS
A NEED FOR THE INVESTIGATION OF FURTHER NANOPARTICLES
THE POTENTIAL TOXICITY OF ENGINEERED NANOPARTICLES IS AN UNSOLVED ISSUE AND STILL NEEDS TO BE DEALT WITH
THE FUTURE OF NANO AND BIO COLLABORATIONS IS PROMISING

NANOPARTICLE ADDED VALUE IN DRUG DELIVERY

CASE STUDY -- UNIVERSITY OF MICHIGAN’S NANOPARTICLE-BASED PAIN RELIEF STUDY FOR MILITARY BATTLEFIELD USE
CASE STUDY -- ACUSPHERE’S HYDROPHOBIC DRUG DELIVERY SYSTEM (HDDS™) FOR
REFORMULATION OF HYDROPHOBIC DRUGS
CASE STUDY -- IMARX’S HYDROPLEX™ PLATFORM FOR DELIVERING HYDROPHOBIC DRUGS
CASE STUDY – ALPHARX’S NANOPARTICLE DRUG DELIVERY PLATFORM FOR ANTIBIOTIC DRUGS
CASE STUDY – CYTRX’S RNAI NANOPARTICLE DELIVERY TECHNOLOGY FOR RNAI THERAPEUTICS

INVESTING IN NANOPARTCLE-ENABLED DRUG DELIVERY INDUSTRY

CASE STUDY – NANOTHERAPEUTICS’ COMMERCIALISATION STRATEGY
Business Summary
Technology Core Competency
Commercialisation Strategy
Available Market
CASE STUDY – HOW CAN NANOVINDEX’S NANOPARTICLE HYDROGEL COMPOSITES ADD VALUE FOR
DRUG DELIVERY INVESTORS
Business Summary.....80
Technology Core Competency
How Nanoparticles Add Value For Investors In Drug Delivery Company
Comercialization Strategy
Available Market
CASE STUDY -- KEYSTONE NANO’S MOLECULAR DOTS (MDS) COMMERCIALISATION STRATEGY
Business Summary
Technology Core Competency
How Nanoparticles Add Value For Investors In Drug Delivery Company
Commercialisation Strategy
Available Market
Intellectual Property
CASE STUDY – NANOCARRIER’S PROTEINS NANOENCAPSULATION SEEKING OUT BIG BIOTECH BUSINESS
Business summary.
Technology Core Competency
How Nanoparticles Add Value For Investors In Drug Delivery Company
Commercialisation Strategy
Available Market
CASE STUDY -- NANOBIOMAGNETICS’ BUSINESS MODEL FOR ORGAN-ASSISTING-DEVICE (OAD)
TECHNOLOGIES
Business Summary
Technology Core Competency
How Nanoparticles Add Value For Investors In Drug Delivery Company
Commercialisation Stratety
Intellectual Property
CASE STUDY – HOW CAN AVIDIMER THERAPEUTICS’ AVIDIMERS PLATFORM TECHNOLOGY ADD VALUE FOR DRUG DELIVERY INVESTORS
Business Summary
Techonology Core Competency
How Nanoparticles Add Value For Investors In Drug Delivery Company
Commercialisation Strategy
CASE STUDY -- CAPSULUTION’S COMMERCIALISATION STRATEGY FOR LBL-TECHNOLOGY®-BASED
DRUG DELIVERY SYSTEMS
Business Summary
How Nanoparticles Add Value For Investors In Drug Delivery Company
Commercialisation Strategy
CASE STUDY -- ACCESS PHARMACEUTICALS’ PRODUCT PIPELINE FOR COBALAMIN™- MEDIATED
DISEASE TARGETING
Business Summarry
Technology Core Competency
How Nanoparticle Add Value For Investors In Drug Delivery Company
CASE STUDY - AZAYA THERAPEUTICS’ PRODUCT PIPELINE FOR PROTEIN STABILIZED LIPOSOME (PSL™)
NANOTECHNOLOGY
Business Summary
Technology Core Competency
Commercialisation Strategy

NANOPARTICLE DRUG DELIVERY SYSTEM BY DELIVERY METHOD/ROUTES OF
ADMINISTRATION

DELIVERY METHOD
ORAL ADMINISTRATION
Case Study -- Access Pharmaceuticals’ Cobalamin™ - Mediated Disease Targeting
Case Study – Nanotherapeutics’ Nanoparticle Oral Applications
Case study – SoluBest’s Solumer™ Technology Platform
TRANSDERMAL DELIVERY
Case Study -- Biophan Technologies’ Transdermal Patches By Using Halloysite Nanotubes
Technology
Case Study -- The Interstitial NanoSystems’ Transdermal Nanoparticle Delivery
INJECTABLE DELIVERY
Case Study -- Biophan Technologies’ Nanomagnetic Guided Drug Delivery
Case Study -- Nanobiotix’s NanoBiodrugsTM
TOPICAL DELIVERY
Case Study -- Starpharma’s VivaGel
Case Study – Nanotherapeutics’ NanoDRY™; NanoCOAT™ and NanoQUAD™ Drug Delivery Systems.
INHALED/NASAL/PULMONARY DELIVERY
Case Study -- Interstitial NanoSystem’s Pulmonary Nanoparticle Delivery
IMPLANTABLE DELIVERY
Case Study -- Biophan Technologies’ Nanomagnetic Drug Delivery: Drug-Eluting Implanted Devices
Case Study -- NanoBioMagnetics’ Organ-Assisting-Device (OAD) Technologies

NANOPARTICLE DRUG DELIVERY SYSTEM BY THERAPEUTICS

THERAPY
CANCER THERAPY
Case Study -- Nanocarrier’s Micellar Nanoparticles And Key Delivery Systems
Case Study -- Abraxis BioScience’s Nanoparticle Albumin Bound (nabTM) Technology Platform
Case Study -- Abraxis BioScience’s Abraxane®
Case Study -- Access Pharmaceuticals, Inc.’s Nanoparticle Aggregate Drug Delivery Technology
Case Study -- Access Pharmaceuticals’ ProLindac™.
Case Study -- Advance Nanotechnologies’ Nanoparticle Composites Drug Delivery System
Case Study -- BioAlliance Pharma’s Nanoparticle-based Transdrug® Drug Delivery Platform
Case Study -- Cornerstone Pharmaceuticals’ Emulsiphan™ Nanoparticle Tumor Targeting
Technology
Case Study -- Insert Therapeutics’ Nanoparticle Mediated Drug Delivery System
Case Study -- Keystone Nano’s Molecular Dots (MDs) Drug Delivery Technology
Case Study -- Magforce Nanotechnologies’ MagForce® Nanoparticles
Case Study -- Tempo Pharmaceuticals’ Nanocell™ Technology
Case Study -- Aphios Corporation’s TaxosomesTM
VACCINES
Case Study -- Biosante Pharmaceuticals’ Calcium Phosphate Nanoparticles (CAP)-based
Technology
Case Study -- NanoMed's Nanotemplate Engineering Technology
Case Study -- Novavax’s Micellar Nano Particles (MNPs), Novasome® Paucilamellar Vesicles And Virus-Like Particle (VLP) Technology
ANTIBODY
Case Study -- Ablynx’s Nanobody® Platform
Case Study – NanoViricides’ Targeted Anti-Viral Therapeutics Platform
DNA BASED THERAPY
Case Study -- Introgen Therapeutics’ Nanoparticle Drug Delivery Technology Platform
Case Study -- Asklêpios BioPharmaceutical Inc.’s Biological Nano Particles (BNP™) Platform
Case Study -- Copernicus Therapeutics’ DNA Nanoparticles
Case Study -- Calando Pharmaceuticals’ Targeted Polymeric Nanoparticle Delivery Systems And Sirna Design
Case Study -- Epeius Biotechnologies’ Targeted Delivery System (TDS) Technology
Case Study -- Intradigm’s Nanoparticle-Based Delivery System
Case Study -- Flamel Technologies’ Medusa® Delivery Platform
Case Study -- Novosom AG’s SMARTICLES® and CAGICLES® Technology
Case Study -- Transgenex Nanobiotech’s SiPlex™ Technology

NANOPARTICLE DRUG DELIVERY SYSTEM BY TECHNOLOGY

NANOPARTICULATE ENCAPSULATION
Case Study -- Aquanova’s Nanoparticulate Encapsulation Technology
Case Study -- Bio Delivery Sciences International’s Bioral® Encochleation Drug Delivery
Technology
Case Study -- Capsulution’s LBL-Technology®-based Drug Delivery Systems
Case Study -- Ceramisphere’s Encapsulation Technology
Case Study – Genesegues’ Targeted Nanocapsule Technology
Case Study – iCeutica’s Encapsulated Organic Nanoparticles (EON™) Platform
Case Study – NutraLease’s Nanoencapsulation Technology
THE DENDRIMER-BASED TARGETED THERAPEUTICS TECHNOLOGY
Case Study -- Avidimer Therapeutics’ Avidimers
Case Study -- Dendritic Nanotechnologies Inc. (DNT)’S Priostar™ Dendrimer Nanotechnology
LIPOSOMES NANOTECHNOLOGY
Case Study -- Azaya Therapeutics’ Protein Stabilized Liposome (PSL) Nanotechnology Platform
Case Study -- LiPlasome Pharma’s Liposome-based Drug Delivery Platform
NANOTUBE TECHNOLOGIES
Case Study -- Biophan Technologies’ Halloysite Nanotube Technologies
Case Study -- NanoCyte’s Nanotube Technology-based Drug Delivery System
NANOSHELL TECHNOLOGY
Case Study -- Nanospectra Biosciences’ AuroLase™ Cancer Therapy
NANOPARTICLES COATING TECHNOLOGY
Case Study -- Cytimmune’s Colloidal Gold Nanoparticle-Based Delivery Platform
SILICA-CHITOSAN NANOCOMPOSITE
Case Study -- ISTN’s Silica-Chitosan Nanocomposties For Peptic Ulcer Treatment
NANOCRYSTAL TECHNOLOGY
Case Study -- Elan’s NanoCrystal® Technology
NANOSOME TECHNOLOGY
Case Study -- Molecular Therapeutics’ Nanosome Platform
NANOSUSPENSION TECHNOLOGY
Case Study -- Baxter BioPharma Solutions’ NANOEDGE Dispersion Technology
POLYMER THERAPEUTICS
Case Study – Labopharm’s Polymeric Nano-Delivery System™
Reproduction in whole or in part without permission of Científica is prohibited.
Case Study -- Intezyne Technologies’ IVECT™ Drug Delivery Platform (DDP)
Case Study -- Insert Therapeutics’ Nanoparticle Mediated Drug Delivery System

APPENDIX 1: LIST OF NANOPARTICLE DRUG DELIVERY PLATFORMS/TECHNOLOGIES

APPENDIX 2: NANOPARTICLES IN DRUG DELIVERY PRODUCTS ON THE MARKET OR IN CLINICAL PHASE 1/2/3

APPENDIX 3: OVERVIEW OF NANOPARTICLE APPLICATIONS IN DRUG DELIVERY

APPENDIX 4: DRUG DELIVERY COMPANY - COMPANIES WHO PRODUING
NANOPARTICLES/TECHNOLOGIES ENABLE BETTER DRUG DELIVERY COMPOUNDS

APPENDIX 5: DRUG FORMULATION COMPANY - COMPANIES WHO USING
NANOPARTICLE-ENABLED FORMULATIONS TO ENHANCE DRUG DELIVERY

Table of Exhibits

Exhibit 1: Nanoparticle Drug Delivery System By Delivery Method/Routes Of
Administration
Exhibit 2: Nanoparticle Drug Delivery System By Therapeutics
Exhibit 3: Nanoparticle Drug Delivery System By Technology
Exhibit 4: Nanoparticle Drug Delivery Technology Used By Drug Formulation Company And Drug Delivery Company By Nation
Exhibit 5: Phama R&D Spend On Nanotech
Exhibit 6: Share Of DDS Market
Exhibit 7: Value Of Nanotechnology Based DDS 2006-2012
Exhibit 8: Value Of Nanotechnology Based DDS 2006-2015
Exhibit 9: Value Of Nanotechnology Based DDS 2006-2015
Exhibit 10: Share of DDS Market
Exhibit 11: Impace Of Nanotechnologies On Drug Delivery Market 2006-2015
Exhibit 12: Value Of Nanotparticle Based DDS 2006-2012
Exhibit 13: Value Of Nanotparticle Based DDS 2006-2015
Exhibit 14: Value Of Nanostructure Based DDS 2006-2012
Exhibit 15: Value Of Nanostructure Based DDS 2006-2015
Exhibit 16: Value Of Dendrimer Based DDS 2006-2012
Exhibit 17: Value Of Dendrimer Based DDS 2006-2015
Exhibit 18: Future Medical Practice Estimations Within The Drug Encapsulation/Drug Delivery/Drug Targeting Sector
Exhibit 19: Estimated Global Production Rates For Various Nanomaterials And Devices (2003–2004)
Exhibit 20: Average Technology Targets Of Nanoparticles In The Pharmaceutical Sector
Exhibit 21: Future Development Of Diagnostics And Therapy By The Means Of Advanced Medical Tools
Exhibit 22: Nanotechnology Implications On Medical Sector
Exhibit 23: Pharmaceutical Value Chain And Involvement Of The Four Technologies
Exhibit 24: Drug Encapsulation/Drug Delivery/Drug Targeting
Exhibit 25: Typical Image of Colloidal Gold Nanoparticles
Exhibit 26: FDA Approved Nanoparticle DDS
Exhibit 27: The Most Appropriate Types of Nanoparticles for Drug Delivery
Exhibit 28: Overview On The Most Appropriate Types Of Nanoparticles Used In Drug Encapsulation/Drug Delivery/Drug Targeting
Exhibit 29: Schematic Representation of Polymer Therapeutics Now In or Progressing Towards Clinical Development
Exhibit 30: Schematic Illustration Of The Therapeutics And Technologies In Clinical Development And/Or On The Market As Treatment For Cancer That Can Be Viewed As Nanomedicines
Exhibit 31: Trend In Issued Patent Involving Nanoparticles For Drug Delivery (1992-2004)
Exhibit 32: Goal Of Select Nanoparticle Drug Delivery Patents Issued During 1992-2004
Exhibit 33: Most Important Applications Of Nanotechnology In The Medical Sector
Exhibit 34: Typical Configurations Utilised In Nanoparticles Applied To Medical Or Biological Problems
Exhibit 35: Nanoparticles As Imaging Agents And Drug Carriers
Exhibit 36: A Representative Photograph of Nanoparticles
Exhibit 37: World Nanotechnology Industry Focus In 2004 By Sector --
Nanobiotechnology Companies Represent Around 8% Of The Overall Industry
Exhibit 38: Summary Of Application Areas For Nanoscale Pharmaceuticals And Medicine In Drug Delivery
Exhibit 39: Trend In Issued Patent Involving Nanoparticle
Exhibit 40: Expected Evident Bottlenecks In R&D In Drug Encapsulation/Drug
Delivery/Drug Targeting
Exhibit 41: Expected Barriers In The Development Of Particular Types Of Nanoparticles
Exhibit 42: Specified Expected Barriers In The Development Of Particular Types Of Nanoparticles
Exhibit 43: The Representation Of HydroPlex™
Exhibit 44: Slow Releasing Feature Of Encapsulated G-CSF
Exhibit 45: NanoCarrier Product Pipeline
Exhibit 46: Business Model of NanoCarrier
Exhibit 47: NanoBioMagnetics’ Investor Business Model
Exhibit 48: Avidimer Therapeutics’ Avidimers Technology
Exhibit 49: Avidimer Therapeutics’ Avidimers Technology
Exhibit 50: Access Pharmaceuticals Product Pipeline
Exhibit 51: Azaya Therapeutics Product Pipeline
Exhibit 52: Access Pharmaceuticals’ Cobalamin™
Exhibit 53: Cobalamin™ Mechanism of Absorption
Exhibit 54: A Study Of The Oral Administration Of Cobalamin™-Coated Nanoparticles Compared To Uncoated Nanoparticles In Rodents
Exhibit 55: The Effectiveness Of Oral Drug Delivery Using Cobalamin™-Coated Nanoparticles
Exhibit 56: Biophan Technologies’ Transdermal Patch
Exhibit 57: Rendering Of Nanotech-Based Bandage
Exhibit 58: Interstitial NS Transdermal Delivery Applicator Prototype
Exhibit 59: Biophan Technologies’ Nanomagnetic Particle
Exhibit 60: Injected Drug
Exhibit 61: Drug Drawn To Tumor
Exhibit 62: Activating Drug In Tumor
Exhibit 63: Nanobiotix’s NanoBiodrugsTM
Exhibit 64: Illustration of Starpharma’s VivaGel™ In Proposed Single-use Applicator
Exhibit 65: Interstitial NS Portable Personal Inhaler; Utilises SAW Delivery For Non-Invasive, Pain-Free, User-Controlled Delivery Of Large Molecule Drugs
Exhibit 66: The Comparison Of Conventional Passive Technology And Biophan Active Technology By Using Nanomagnetic Technology
Exhibit 67: Polymer Matrix
Exhibit 68: Particles Loaded On Stent Coating
Exhibit 69: Drugs Bound To Nanomagnetic Particles
Exhibit 70: EM Signal Releasing Drugs
Exhibit 71: Second EM Signal Releasing Drugs
Exhibit 72: Features Of Nanocarrier's DDS Technologies
Exhibit 73: The Core Technology - Micellar Nanoparticles
Exhibit 74: NanoCarrier’s Micellar Nanoparticles
Exhibit 75: NanoCapTM
Exhibit 76: MediCelleTM
Exhibit 77: NanoCoat System
Exhibit 78: Unique Benefit Of True Nanoparticles In Oncology: Targeting To Tumors
Exhibit 79: Chemistry of ProLindac™
Exhibit 80: Prolindac™ Releases Platinum Much More Rapidly In A Slightly Acidic Environment Compared With An Environment Of The Body’s Normal
Physiological pH
Exhibit 81: Emulsiphan™ - Passive Targeting
Exhibit 82: Emulsiphan™ - Active Targeting
Exhibit 83: Insert Therapeutics’ Cyclosert™ Technology
Exhibit 84: A Photomicrograph Of A Nano-Composite Particle
Exhibit 85: A Graphic Representation Of The Molecular Dot
Exhibit 86: An Overview Of Some Features Of Molecular Dot
Exhibit 87: Ceramide MDs Kill Drug-Resistant Breast Cancer Cells
Exhibit 88: BioSante’s Product Pipeline
Exhibit 89: NanoMed's Nanotemplate Engineering Technology
Exhibit 90: Confocal Pictures of DC’s Starined Red With Anti-CD11c And Green Nanoparticles
Exhibit 91: Novavax’s Micellar Nano Particles (MNPs)
Exhibit 92: The Comparison of Convential Antibody and Ablynx’s Nanobody
Exhibit 93: Nanoviricides Dismantling MCMV Seen In TEM
Exhibit 94: Nanoviricides Product Illustration
Exhibit 95: NanoViricides Product Pipeline
Exhibit 96: How BNP Works
Exhibit 97: AskBio’s Product Pipeline
Exhibit 98: Nature Compacts DNA
Exhibit 99: RNA Interference ("RNAi")
Exhibit 100: Calando’s siRNA Technology
Exhibit 101: Preclinical Data That Demonstrate Sequence-Specific Gene Inhibition In Tumors From The Systemic Administration Of Targeted Formulations Of Sirna
Exhibit 102: qRT-PCR Result Summary
Exhibit 103: Layers/Functions Of Intradigm’s Nanoparticle
Exhibit 104: Intradigm Nanoparticle Delivery System for RNAi
Exhibit 105: Potential Targets For Which Active Sirnas Have Been Identified
Exhibit 106: Flamel’s Unique Method For The Controlled Release Of Proteins And Peptides
Exhibit 107: Flamel’s Medusa® Technology
Exhibit 108: Flamel’s Medusa® Product Pipeline
Exhibit 109: Novosom AG’s SMARTICLES®
Exhibit 110: An Animation Of The Process By Which SMARTICLES® Deliver DNA Based Therapeutics Inside A Cell
Exhibit 111: Novosom’s CAGICLES®
Exhibit 112: NovaSOL Product Micelle
Exhibit 113: AQUANOVA Solubilisates (Examples)
Exhibit 114: AQUANOVA Capsules
Exhibit 115: Bio Delivery Sciences International’s Bioral® Encochleation Drug Delivery Technology
Exhibit 116: Determination Of Residual Moisture By Karl-Fischer-Methodd
Exhibit 117: Overview Of The Encapsulation Process
Exhibit 118: Overview Of The Complexation Process
Exhibit 119: How Scalable Technology Addresses Industry’s Key Problems In
Biopharmaceutical Delivery
Exhibit 120: Genesegues’ Nanoencapsulated Therapeutic
Exhibit 121: iCeutica’s EON Process (Example)
Exhibit 122: NutraLease’s Nanoencapsulation Technology
Exhibit 123: The Nano-Sized Self-Assembled Structured Liquids (NSSL) Technology
Exhibit 124: A Phase Diagram Of The Possible Combinations To Form The Nano-Sized Self-Assembled Structured Liquids (NSSL)
Exhibit 125: Nutralease’s FNV technology
Exhibit 126: The Release Of Nutralease’ Nutraceuticals Into The Membrance Between The Digestive System And The Blood
Exhibit 127: NutraLease Products
Exhibit 128: Avidimer Therapeutics’ Avidimers
Exhibit 129: Illustration Of The Dendrimer Compared In Size To Hemoglobin
Exhibit 130: Priostar™ Product Pipeline
Exhibit 131: DNT’s PrioFect™
Exhibit 132: DNT’s STARBURST® Dendrimers
Exhibit 133: An Example Of Phospholipase A2 Catalyzed Hydrolysis Of A Lipid Membrane Visualized By Atomic Force Microscopy
Exhibit 134: NanoCyte mode of operation
Exhibit 135: How Does Colloidal Gold Work
Exhibit 136: CytImmune Product pipeline
Exhibit 137: Molecular Therapeutics’ Dynamic Nano-Platform
Exhibit 138: Nanoedge Technology Features
Exhibit 139: Nanoedge Solid Partilce Technologies
Exhibit 140: How Do Labopharm’s Polymeric Nano-Delivery System™ Work
Exhibit 141: Labopharm’s Technologies For In Vivo Delivery
Exhibit 142: Labopharm’s Therapeutic Pipeline
Exhibit 143: Labopharm’s Business Development
Exhibit 144: Intezyne Technologies’ IVECT™ Drug Delivery Platform
Exhibit 145: Insert Therapeutics’ Cyclosert™ Polymers
Exhibit 146: Insert Therapeutics’ Cyclosert™ Multiple Formulations

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos